Who is sponsoring NCT02040818?

NCT02040818 is sponsored by University of California, San Diego.

What drugs are being tested in NCT02040818?

Interventions in NCT02040818: tigecycline, N-acetylcysteine, heparin combination, guide-wire exchange.

What condition does NCT02040818 study?

NCT02040818 studies Hemodialysis Catheter-related Bacteremia.

Is NCT02040818 still recruiting?

NCT02040818 is currently withdrawn. Last updated 6 October 2015.

Last reviewed 2015-10-06 · How we verify

NCT02040818

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia

Withdrawn Phase 2/Phase 3 Last updated 6 October 2015

What this trial tests

Phase 2/Phase 3 trial testing tigecycline, N-acetylcysteine, heparin combination in Hemodialysis Catheter-related Bacteremia. Withdrawn.

Timeline

1 November 2013

Primary endpoint
1 January 2017

Quick facts

Lead sponsor	University of California, San Diego
Phase	Phase 2/Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Masking	none
Start date	1 November 2013
Primary completion	1 January 2017
Sites	1 location across United States

Drugs / interventions tested

tigecycline, N-acetylcysteine, heparin combination — full drug profile →
guide-wire exchange

Conditions studied

Hemodialysis Catheter-related Bacteremia — all drugs for Hemodialysis Catheter-related Bacteremia →

Sponsor

University of California, San Diego

Who can join

Adults 18 to 100, any sex, with Hemodialysis Catheter-related Bacteremia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Treatment Success
Time frame: 28 days
The primary outcome is successful treatment of infection defined as clinical and microbiologic resolution of the initial bacteremia with absence of persistent or recurrent catheter-related bacteremia at day 28 (one week after end of treatment).

Sponsor's own description

Patients who undergo hemodialysis via a tunneled catheter often develop bloodstream infections that arise from the catheter. There are several management options for treatment of such an infection, though the best option is not clearly delineated. Standard of care options include exchanging the catheter for a new one over a guide-wire and instilling a high concentration of an antibiotic directly into the catheter lumen. The investigators are planning to treat hemodialysis catheter bloodstream infections by one of two strategies: 1. Use of a novel antibiotic lock solution Or 2. Changing out the infected catheter for a new one. Both these options have comparable cure rates as shown in the medical literature. After obtaining informed consent, patients will be randomized to either treatment arm and will continue to receive all other standard medical care. Specific Aim: To conduct a randomized clinical trial to demonstrate that the use of a novel antibiotic lock solution (consisting of N-acetylcysteine, tigecycline and heparin) is non-inferior to guide-wire exchange in the treatment of hemodialysis catheter-related bacteremia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis.
Almeida BM, Moreno DH, Vasconcelos V, Cacione DG. · · 2022 · cited 19× · PMID 35363884 · DOI 10.1002/14651858.cd013554.pub2

Verify or expand the search:

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02040818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 6 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02040818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing